Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 127-130

  Berg, Stacey L ^a   Aleksic, Alexander ^a   McGuffey, Leticia ^a   Dauser, Robert ^a   Nuchtern, Jed ^a   Bernacky, Bruce ^b   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cerebrospinal fluid; Pharmacokinetics; Plasma; Rebeccamycin

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); ANTINEOPLASTIC AGENT; DIAZEPAM; PROCHLORPERAZINE; REBECCAMYCIN;

AGITATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NAUSEA; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 3843130773     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0787-0     Document Type: Article

References (18)

1. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K (1987) Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo) 40:668
2. Kaneko T, Wong H, Utzig J, Schurig J, Doyle T (1990) Water soluble derivatives of rebeccamycin. J Antibiot (Tokyo) 43:125
3. Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A, Rubin E (1999) The camptothecin-resistant topoisomerase 1 mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry 38:8605
4. Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M (1997) DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 36:3917
5. Bailly C, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M, Waring MJ (1998) Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol Pharmacol 53:77
6. Bailly C, Qu X, Anizon F, Prudhomme M, Riou JF, Chaires JB (1999) Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol Pharmacol 55:377
7. Woo MH, Vance JR, Marcos AR, Bailly C, Bjornsti MA (2002) Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J Biol Chem 277:3813
8. Whitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD (1998) In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. J Pediatr Hematol Oncol 20:136
9. Dowlati A, Hoppel CL, Ingalls ST, Majka S, Li X, Sedransk N, Spiro T, Gerson SL, Ivy P, Remick SC (2001) Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 19:2309
10. Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G (2002) Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res 8:2193
11. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK (2001) Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 19:2937
12. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:522
13. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy, Washington, DC
14. D'Argenio D, Schumitzky A (1992) ADAPT II user's guide. Biomedical Simulations Resource, University of Southern California, Los Angeles
15. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165
16. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
17. Langevin AM, Whitman SD, Kuhn JG, Weintraub ST, Baruchel S, Furman W, Bernstein M, Blaney S, Vietti T (2003) Phase I trial of rebeccamycin analog (NSC# 655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 25:526
18. Donelli M, Zucchetti M, D'Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251